Question 1

When was Relmada Therapeutics, Inc founded?

Accepted Answer

Relmada Therapeutics, Inc was founded in 2004.

Question 2

Where is Relmada Therapeutics, Inc headquarters?

Accepted Answer

Relmada Therapeutics, Inc headquarters is in 2222 Ponce De Leon Blvd, Floor 3, Coral Gables, Florida 33134, US.

Question 3

How many employees does Relmada Therapeutics, Inc have?

Accepted Answer

Relmada Therapeutics, Inc has 33 employees.

Question 4

What sector does Relmada Therapeutics, Inc operate in?

Accepted Answer

Relmada Therapeutics, Inc is in Pharmaceutical Manufacturing sector.

Question 5

What does Relmada Therapeutics, Inc Do ?

Accepted Answer

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.  REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD in adjunctive and monotherapy Phase 3 studies. The ongoing RELIANCE Phase 3 Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo in tested measures of depression. The Phase 2 study also showed a favorable safety, tolerability, and pharmacokinetics profile of REL-1017, consistent with results observed in the previously completed Phase 1 studies.For media inquiries, please contact relmada@fischtankpr.com.

Question 6

What is the Legal Name of Relmada Therapeutics, Inc ?

Accepted Answer

The legal name of Relmada Therapeutics, Inc is Relmada Therapeutics, Inc.

Question 7

When was Relmada Therapeutics, Inc incorporated ?

Accepted Answer

Relmada Therapeutics, Inc was incorporate on 2004

Question 8

What is the registered address of Relmada Therapeutics, Inc  ?

Accepted Answer

The registered address of Relmada Therapeutics, Inc is 2222 Ponce de Leon Blvd, Floor 3, Coral Gables, Florida 33134, US

Trademark Name/Patent Name	Application No	Date

We are unable to find trademarks of Relmada Therapeutics, Inc as on December 14, 2025

Relmada Therapeutics, Inc Trademarks and Patents

Relmada Therapeutics, Inc- Phone & Email of Top Employees & Directors

Fabiana Fedeli

Download our free EasyLeadz Chrome extension. Find contact numbers for 250M+ people on Internet directly.

The most accurate data ever

Support

Company

Email us

Relmada Therapeutics, Inc Trademarks and Patents

Relmada Therapeutics, Inc- Phone & Email of Top Employees & Directors

Fabiana Fedeli

Download our free EasyLeadz Chrome extension. Find contact numbers for 250M+ people on Internet directly.

The most accurate data ever

Want contacts of top management of Relmada Therapeutics, Inc?